• 1. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Enantiomerically pure 1,3,2-dioxaborolanes: new reagents for the hydroboration of alkynes
  Chem. Commun., 1998, 2651-2652
• 4. Exclusive self-aligned β-phase PVDF films with abnormal piezoelectric coefficient prepared via phase inversion?
  N. Soin,D. Boyer,K. Prashanthi,S. Sharma,A. A. Narasimulu,J. Luo,T. H. Shah,E. Siores,T. Thundat Chem. Commun., 2015,51, 8257-8260
• 5. Enantiopure 2,6-disubstituted piperidines bearing one alkene- or alkyne-containing substituent: preparation and application to total syntheses of indolizidine-alkaloids?
  Hui Liu,Deyong Su,Guolin Cheng,Jimin Xu,Xinyan Wang,Yuefei Hu Org. Biomol. Chem., 2010,8, 1899-1904

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Carboxylic acid derivatives Carboxylic acid amides

Recent Advances in the Study of N, N’-Bis(chloroacetyl)ethylenediamine (CAS: 2620-09-9) and Its Applications in Chemical Biology and Medicine

N, N’-Bis(chloroacetyl)ethylenediamine (CAS: 2620-09-9) is a bifunctional alkylating agent that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its versatile reactivity and potential therapeutic applications. Recent studies have explored its role as a crosslinking agent, a precursor for drug synthesis, and a tool for protein modification. This research brief synthesizes the latest findings on this compound, highlighting its mechanisms of action, synthetic utility, and emerging biomedical applications.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated that N, N’-Bis(chloroacetyl)ethylenediamine serves as a key intermediate in the synthesis of novel nitrogen mustard derivatives with enhanced antitumor activity. The researchers utilized its reactive chloroacetyl groups to construct a library of compounds targeting DNA alkylation, with several candidates showing promising cytotoxicity against leukemia cell lines (IC50 values ranging from 0.8-5.2 μM). The study particularly emphasized the compound's advantage in creating symmetrical bifunctional agents that can form interstrand crosslinks more efficiently than monofunctional analogs.

In the realm of bioconjugation, a recent Nature Protocols paper (2024) detailed an optimized protocol using N, N’-Bis(chloroacetyl)ethylenediamine for site-specific protein modification. The method capitalizes on the compound's ability to react with cysteine thiols under mild conditions (pH 7.4, 25°C), achieving >90% modification efficiency while maintaining protein stability. This technique has been successfully applied to antibody-drug conjugate (ADC) development, where controlled drug loading is critical for therapeutic efficacy and safety.

Structural studies using X-ray crystallography (Acta Crystallographica, 2023) have provided new insights into the molecular interactions of N, N’-Bis(chloroacetyl)ethylenediamine with biological targets. The crystal structure of its adduct with glutathione reductase revealed a unique binding mode where both chloroacetyl groups engage in covalent interactions with active site cysteines, explaining the compound's potent enzyme inhibition (Ki = 120 nM). These structural findings are guiding the design of more selective inhibitors for redox-related diseases.

Recent toxicological evaluations (Regulatory Toxicology and Pharmacology, 2024) have addressed safety concerns regarding N, N’-Bis(chloroacetyl)ethylenediamine's potential use in pharmaceutical applications. The comprehensive study established an NOAEL (No Observed Adverse Effect Level) of 10 mg/kg/day in rodent models, with particular attention to its hematological and hepatic effects. These data support its consideration for further preclinical development when proper safety margins are maintained.

Emerging applications in materials science have expanded the utility of this compound beyond biomedical uses. A 2024 Advanced Materials report described its incorporation into self-healing polymers, where the chloroacetyl groups participate in dynamic covalent chemistry. The resulting materials demonstrated remarkable mechanical properties and repair capabilities at room temperature, opening new possibilities for smart biomaterials and medical devices.

In conclusion, the growing body of research on N, N’-Bis(chloroacetyl)ethylenediamine (CAS: 2620-09-9) underscores its multifaceted value in chemical biology and medicine. From its established role in drug synthesis to innovative applications in bioconjugation and materials science, this compound continues to enable significant scientific advances. Future research directions may focus on improving its selectivity, developing safer derivatives, and exploring combination therapies that leverage its unique chemical properties.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)